Last reviewed · How we verify

NCT06309641

Methemoglobinemia Following Intravenous Iron Treatment

Completed Last updated 9 December 2025
What this trial tests

trial testing Blood sample after treatment in Methemoglobinemia in 50 participants. Completed in 13 October 2025.

Timeline
2 September 2024
Primary endpoint
13 October 2025
13 October 2025

Quick facts

Lead sponsorClaudia Seiler
StatusCompleted
Study typeOBSERVATIONAL
Enrollment50
Start date2 September 2024
Primary completion13 October 2025
Estimated completion13 October 2025
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Claudia Seiler

Who can join

18 and older, any sex, with Methemoglobinemia or Anemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Methemoglobinemia as a side effect of treatment with intravenous iron has not previously been described. This study aims to assess methemoglobin levels in patients with anemia following treatment with intravenous iron, administered as ferric carboxymaltose or ferric derisomaltose.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06309641.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing